PDF Cover

Gadopiclenol Market

The market for Gadopiclenol was estimated at $392 million in 2024; it is anticipated to increase to $971 million by 2030, with projections indicating growth to around $2.07 billion by 2035.

Report ID:DS1802233
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Gadopiclenol
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Gadopiclenol Market Outlook

Revenue, 2024

$392M

Forecast, 2034

$1.78B

CAGR, 2025 - 2034

16.3%

The Gadopiclenol industry revenue is expected to be around $456.2 million in 2025 and expected to showcase growth with 16.3% CAGR between 2025 and 2034. The rapid expansion of the Gadopiclenol market is closely connected to essential factors that confirm its continued importance in the industry landscape. The main drivers supporting this market growth encompass advancements in healthcare and pharmaceutical technology advancements while meeting the rising need for cutting edge diagnostic solutions and addressing the increasing global emphasis on disease detection and prevention efforts. Given its performance within this supportive atmosphere Gadopiclenol remains a significant player, in influencing market dynamics and consumer choices worldwide.

In line with these market trends and developments Gadopiclenol solidifies its standing through attributes and diverse uses in various fields. Known for its contrasting qualities in medical imaging Gadopiclenol has improved the precision of diagnostic tests especially, in Magnetic Resonance Imaging (MRI).

Gadopiclenol market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Gadopiclenol Market Outlook

Market Key Insights

  • The Gadopiclenol market is projected to grow from $392.3 million in 2024 to $1.78 billion in 2034. This represents a CAGR of 16.3%, reflecting rising demand across Magnetic Resonance Imaging Contrast Agent, Radiography, and Drug Development & Research.

  • Bayer Healthcare, Bracco Imaging S.p.A, GE Healthcare are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Gadopiclenol market and are expected to observe the growth CAGR of 15.6% to 22.8% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 12.2% to 17.0%.

  • Transition like Revolutionary Advancements in Magnetic Resonance Imaging is expected to add $61 million to the Gadopiclenol market growth by 2030.

  • The Gadopiclenol market is set to add $1.4 billion between 2024 and 2034, with manufacturer targeting Clinical Trials & Diagnostic Imagery Application projected to gain a larger market share.

  • With

    rising mri procedure volumes and demand for safer high-relaxivity contrast agents, and

    Shift Toward Macrocyclic Gadolinium Agents in Regulated Imaging Markets, Gadopiclenol market to expand 353% between 2024 and 2034.

gadopiclenol market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Gadopiclenol - Country Share Analysis

Opportunities in the Gadopiclenol

Countries like India and Brazil are also seen as promising markets for Gadopiclenol due to their advancing healthcare systems and expanding populations healthcare requirements that highlight the importance of precise diagnosis in these areas—creating a growing need for efficient contrast agents such, as Gadopiclenol.

Growth Opportunities in North America and Europe

In North America. A significant market for Gadopiclenol. There is competition among manufacturers that drives continuous advancements in how the product is used. MRI contrast agents are leading the market thanks to the use of MRI imaging in diagnosing diseases. Gladopiclenol is in demand for neurological and cardiovascular imaging due to its effectiveness and safety features. The rising prevalence of illnesses is also contributing to the need, for more advanced diagnostic methods. Furthermore in this region Gadopiclenols market growth potential is bolstered by the regulatory standards in the pharmaceutical and healthcare industry here The increasing investment in healthcare infrastructure and the rising awareness of the significance of early diagnosis also play crucial roles in expanding Gadopiclenols market presence, in North America.
Europe has a foothold in the worldwide Gadopiclenol market thanks to the strong presence of top pharmaceutical firms and research centers on the continent. Experts believe that Europe shows promise for Gadopiclenol due to the rising need for cutting edge diagnostic tools to accurately diagnose diseases. Furthermore the advancement of medicine and the growing use of AI and ML in healthcare contribute to the growth of the Gadopiclenol market, in Europe. In Europe's focus on research and development significantly impacts the demand for Gadopiclenol, in the field of oncology diagnostics.

Market Dynamics and Supply Chain

01

Driver: Rising MRI Procedure Volumes and Demand for Safer High-Relaxivity Contrast Agents

The growing global volume of MRI procedures is also a major driver for gadopiclenol adoption, fueled by aging populations and increasing diagnosis of neurological, cardiovascular, and oncologic conditions. Parallel to this growth is also heightened demand for safer contrast agents with lower gadolinium exposure. Gadopiclenol’s high relaxivity allows effective imaging at reduced doses, addressing clinician concerns around gadolinium retention. Technological also advances in high-field MRI systems further amplify the need for contrast agents that deliver sharper imaging performance without increasing patient risk, positioning gadopiclenol favorably in premium diagnostic settings.
A clear shift toward macrocyclic gadolinium-based contrast agents is also accelerating gadopiclenol demand. Regulatory scrutiny and updated clinical guidelines increasingly favor macrocyclic structures due to their superior stability profile. Hospitals and imaging centers are also replacing older linear agents, particularly in Europe, North America, and Japan. This transition supports steady uptake of gadopiclenol, especially in tertiary care centers seeking compliance, patient safety assurance, and advanced imaging differentiation.
02

Restraint: Regulatory Challenges

The strict regulations and thorough approval procedures in the healthcare industry are factors affecting the Gadopiclenol markets growth potential. Healthcare products must adhere to the rules and standards set by bodies such as the Food and Drug Administration in the United States this often results in delays in releasing new products. In addition, to the time intensive nature of these processes not only obtaining approval can result in significant financial setbacks. The stringent regulations in effect act, as a crucial deterrent but present a hurdle to the growth of the Gadopiclenol market.
03

Opportunity: Expanding Clinical Applications and Strategic Partnerships and Collaborations

The demand for Gadopiclenol is set to rise as it finds uses in medical settings like neurological and vascular imaging due to its exceptional qualities as a contrast agent with improved imaging capabilities and high relaxivity levels making it popular, for complex medical procedures and opening up possibilities for market expansion and advancements in the field.
In the healthcare field today there is a focus and collaboration between companies in order to advance technology and improve imaging techniques being used for medical purposes. Gadopiclenol could become a leading choice in imaging with the help of partnerships, with imaging technology companies.
04

Challenge: Persistent Safety Perceptions Around Gadolinium-Based Contrast Media Usage

Despite improved safety profiles, lingering concerns about gadolinium deposition continue to affect demand behavior. Some clinicians adopt conservative contrast usage protocols or favor non-contrast MRI when feasible. This cautious approach can reduce contrast agent volumes per scan, directly impacting market revenue growth. Public awareness and medico-legal considerations further intensify cautious adoption in certain healthcare systems.

Supply Chain Landscape

1

Raw Material Procurement

BASF SEDow Inc
2

Synthesis & Processing

GE HealthcareLantheus Medical Imaging
3

Manufacturing

Bracco Imaging S.p.A.Bayer AG
4

Distribution & End Use

Diagnostic Imaging CentersMRI CentersHealthcare Providers
Gadopiclenol - Supply Chain

Use Cases of Gadopiclenol in Magnetic Resonance Imaging Contrast Agent & Drug Development & Research

Magnetic Resonance Imaging Contrast Agent : Magnetic resonance imaging remains the primary application for gadopiclenol, predominantly using macrocyclic gadolinium-based formulations administered intravenously in hospital and diagnostic imaging centers. Its high relaxivity enables strong lesion contrast at lower gadolinium doses, supporting safer imaging in neuro, cardiovascular, and oncologic MRI. The application benefits from improved signal clarity and reduced gadolinium retention risk. Guerbet leads this segment with strong clinical validation, while Bayer and Bracco maintain competitive positions through broad MRI contrast portfolios and global distribution strength.
Radiography : Computed Radiography represents a niche and emerging application for gadopiclenol, mainly within experimental and hybrid imaging environments rather than routine clinical use. Highly stable gadolinium chelates are explored for enhanced soft tissue contrast in advanced X-ray and multimodal research settings, typically used by academic institutions and imaging innovators. The advantage lies in superior atomic number properties compared to iodine alternatives. Market participation is limited, with Guerbet and research-focused divisions of GE HealthCare supporting feasibility studies and specialized radiographic contrast development.
Drug Development & Research : Drug development and research increasingly utilize gadopiclenol as a macrocyclic imaging tracer in preclinical MRI studies. Pharmaceutical companies and contract research organizations use it to monitor biodistribution, tumor response, and blood-brain barrier integrity during early-stage trials. Its high relaxivity supports precise imaging with minimal dosing, improving translational accuracy. Guerbet holds a strong position due to dedicated research-grade supplies, while Bayer and Bracco support this application through collaborative imaging platforms and long-standing relationships with global research institutes.

Recent Developments

Recent developments in the gadopiclenol market show rapid clinical adoption and strategic expansion as this next-generation macrocyclic gadolinium-based contrast agent gains traction in diagnostic imaging. High-relaxivity formulations such as Elucirem and Vueway reduce required gadolinium dose while improving lesion visualization, winning industry awards and FDA classification as a Group II agent for enhanced patient safety. A key market trend is the broader shift toward high-performance MRI contrast agents driven by rising imaging procedure volumes and demand for safer, lower-dose diagnostics.

July 2025 : TGA Approval in Australia: In June 2025, Guerbet announced that Australia’s Therapeutic Goods Administration (TGA) approved Elucirem™ (gadopiclenol) for use in contrast-enhanced MRI in adults and children aged 2 years and older, expanding the agent’s global regulatory footprint beyond the United States and European Union. This approval supports broader clinician access and highlights the contrast agent’s high relaxivity benefits.
October 2024 : JFR 2024 Innovation Award: In October 2024, Bracco Imaging announced that Vueway (gadopiclenol) received the Jury’s Favorite Innovation Award at the JFR 2024 event in Paris, recognizing its clinical impact as a high-relaxivity MRI contrast agent requiring reduced gadolinium doses.
December 2023 : EU Marketing Authorization: In December 2023, the European Commission granted Marketing Authorization for Vueway (gadopiclenol) in the European Union after a positive EMA CHMP opinion. This regulatory milestone enabled commercial launch across EU markets for contrast-enhanced MRI in adults and children aged 2 years and older.

Impact of Industry Transitions on the Gadopiclenol Market

As a core segment of the Pharmaceutical industry, the Gadopiclenol market develops in line with broader industry shifts. Over recent years, transitions such as Revolutionary Advancements in Magnetic Resonance Imaging and Integration of Advanced MRI Technologies have redefined priorities across the Pharmaceutical sector, influencing how the Gadopiclenol market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Revolutionary Advancements in Magnetic Resonance Imaging

The introduction of Gadopiclenol as an MRI contrast agent marks a pivotal shift in medical imaging, significantly enhancing the detection and visualization of abnormalities. This innovative agent not only improves diagnostic accuracy but also elevates the overall quality of healthcare services. As medical practitioners increasingly adopt Gadopiclenol for its superior contrast resolution and patient safety, the market is poised for substantial growth. By 2030, the Gadopiclenol market is projected to increase by $61 million, underscoring its transformative impact on MRI procedures and positioning it as a critical asset in advancing diagnostic capabilities within the healthcare sector.
02

Integration of Advanced MRI Technologies

Another key transition involves the integration of advanced MRI technologies such as high-field systems, functional imaging, and AI-assisted diagnostics. These technologies demand contrast agents capable of delivering consistent, high signal performance across complex imaging protocols. Gadopiclenol benefits from this shift by aligning with next-generation MRI requirements. The transition impacts software providers, scanner manufacturers, and pharmaceutical imaging divisions, fostering closer collaboration across the diagnostic ecosystem and reinforcing demand for premium, innovation-driven contrast agents.